Goldman Sachs’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $407M | Buy |
5,082,050
+1,778,338
| +54% | +$147M | 0.05% | 404 |
|
|
2025
Q4 | $282M | Buy |
3,303,712
+424,217
| +15% | +$34.8M | 0.03% | 499 |
|
|
2025
Q3 | $224M | Buy |
2,879,495
+149,647
| +5% | +$11.7M | 0.03% | 559 |
|
|
2025
Q2 | $214M | Buy |
2,729,848
+175,779
| +7% | +$13.1M | 0.03% | 543 |
|
|
2025
Q1 | $185M | Buy |
2,554,069
+361,111
| +16% | +$25.8M | 0.03% | 539 |
|
|
2024
Q4 | $162M | Sell |
2,192,958
-1,021,219
| -32% | -$71.5M | 0.03% | 579 |
|
|
2024
Q3 | $212M | Sell |
3,214,177
-790,194
| -20% | -$57.4M | 0.03% | 495 |
|
|
2024
Q2 | $370M | Buy |
4,004,371
+504,177
| +14% | +$44.6M | 0.06% | 307 |
|
|
2024
Q1 | $334M | Sell |
3,500,194
-12,951
| -0.4% | -$1.09M | 0.06% | 335 |
|
|
2023
Q4 | $268M | Buy |
3,513,145
+52,282
| +2% | +$3.64M | 0.05% | 391 |
|
|
2023
Q3 | $240M | Sell |
3,460,863
-1,257,981
| -27% | -$101M | 0.05% | 363 |
|
|
2023
Q2 | $445M | Sell |
4,718,844
-16,818
| -0.4% | -$1.46M | 0.1% | 189 |
|
|
2023
Q1 | $392M | Buy |
4,735,662
+1,308,749
| +38% | +$103M | 0.09% | 214 |
|
|
2022
Q4 | $256M | Buy |
3,426,913
+166,698
| +5% | +$12.8M | 0.06% | 337 |
|
|
2022
Q3 | $269M | Buy |
3,260,215
+249,875
| +8% | +$24M | 0.07% | 288 |
|
|
2022
Q2 | $286M | Buy |
3,010,340
+506,630
| +20% | +$52.4M | 0.07% | 267 |
|
|
2022
Q1 | $295M | Sell |
2,503,710
-305,591
| -11% | -$34.3M | 0.06% | 307 |
|
|
2021
Q4 | $364M | Buy |
2,809,301
+38,704
| +1% | +$4.51M | 0.07% | 268 |
|
|
2021
Q3 | $314M | Buy |
2,770,597
+397,721
| +17% | +$45.4M | 0.07% | 277 |
|
|
2021
Q2 | $246M | Sell |
2,372,876
-384,211
| -14% | -$36.2M | 0.06% | 336 |
|
|
2021
Q1 | $231M | Sell |
2,757,087
-247,748
| -8% | -$20.9M | 0.06% | 325 |
|
|
2020
Q4 | $274M | Sell |
3,004,835
-1,770,053
| -37% | -$147M | 0.07% | 254 |
|
|
2020
Q3 | $381M | Sell |
4,774,888
-800,989
| -14% | -$62.5M | 0.11% | 166 |
|
|
2020
Q2 | $385M | Sell |
5,575,877
-157,579
| -3% | -$11.2M | 0.12% | 157 |
|
|
2020
Q1 | $360M | Buy |
5,733,456
+323,949
| +6% | +$23.4M | 0.13% | 147 |
|
|
2019
Q4 | $421M | Buy |
5,409,507
+1,835,040
| +51% | +$143M | 0.11% | 187 |
|
|
2019
Q3 | $262M | Sell |
3,574,467
-785,721
| -18% | -$55.2M | 0.08% | 284 |
|
|
2019
Q2 | $269M | Buy |
4,360,188
+358,740
| +9% | +$21.7M | 0.08% | 262 |
|
|
2019
Q1 | $255M | Buy |
4,001,448
+397,296
| +11% | +$22.7M | 0.08% | 264 |
|
|
2018
Q4 | $184M | Sell |
3,604,152
-1,187,865
| -25% | -$60.1M | 0.06% | 338 |
|
|
2018
Q3 | $278M | Sell |
4,792,017
-744,294
| -13% | -$36.4M | 0.07% | 292 |
|
|
2018
Q2 | $269M | Sell |
5,536,311
-1,904,586
| -26% | -$88.9M | 0.07% | 274 |
|
|
2018
Q1 | $346M | Buy |
7,440,897
+409,626
| +6% | +$17.8M | 0.09% | 243 |
|
|
2017
Q4 | $264M | Buy |
7,031,271
+593,730
| +9% | +$21.8M | 0.06% | 347 |
|
|
2017
Q3 | $235M | Sell |
6,437,541
-1,517,553
| -19% | -$57.9M | 0.06% | 361 |
|
|
2017
Q2 | $314M | Buy |
7,955,094
+95,592
| +1% | +$3.49M | 0.08% | 240 |
|
|
2017
Q1 | $246M | Buy |
7,859,502
+945,735
| +14% | +$29.6M | 0.07% | 305 |
|
|
2016
Q4 | $216M | Buy |
6,913,767
+634,110
| +10% | +$20.5M | 0.06% | 367 |
|
|
2016
Q3 | $252M | Buy |
6,279,657
+2,642,772
| +73% | +$99.5M | 0.08% | 255 |
|
|
2016
Q2 | $121M | Sell |
3,636,885
-1,320,789
| -27% | -$45.2M | 0.04% | 559 |
|
|
2016
Q1 | $146M | Sell |
4,957,674
-999,741
| -17% | -$27.6M | 0.05% | 476 |
|
|
2015
Q4 | $157M | Buy |
5,957,415
+2,059,077
| +53% | +$53.5M | 0.05% | 449 |
|
|
2015
Q3 | $92.4M | Sell |
3,898,338
-575,364
| -13% | -$13.9M | 0.03% | 663 |
|
|
2015
Q2 | $106M | Buy |
4,473,702
+937,902
| +27% | +$21.2M | 0.03% | 624 |
|
|
2015
Q1 | $84M | Buy |
3,535,800
+1,402,068
| +66% | +$31.5M | 0.03% | 739 |
|
|
2014
Q4 | $45.3M | Buy |
2,133,732
+787,998
| +59% | +$15.8M | 0.01% | 1187 |
|
|
2014
Q3 | $22.9M | Sell |
1,345,734
-89,106
| -6% | -$1.41M | 0.01% | 1694 |
|
|
2014
Q2 | $20.5M | Sell |
1,434,840
-149,550
| -9% | -$2.03M | 0.01% | 1761 |
|
|
2014
Q1 | $19.6M | Sell |
1,584,390
-286,434
| -15% | -$3.31M | 0.01% | 1783 |
|
|
2013
Q4 | $20.5M | Sell |
1,870,824
-8,978,628
| -83% | -$101M | 0.01% | 1726 |
|
|
2013
Q3 | $126M | Buy |
10,849,452
+7,001,370
| +182% | +$81.9M | 0.05% | 482 |
|
|
2013
Q2 | $43.1M | Buy |
+3,848,082
| New | +$45.5M | 0.02% | 996 |
|
Other funds holding EW
VCM
VPM
Goldman Sachs's EW Position: Q1 2026 in Review
Goldman Sachs increased its Edwards Lifesciences (EW) stake by 54% in Q1 2026, buying an estimated $147M and bringing the position to 5,082,050 shares worth $407M. The position accounts for 0.05% of the portfolio, ranked #404.
Goldman Sachs first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $445M in Q2 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Goldman Sachs held 5,082,050 shares of Edwards Lifesciences worth $407M as of Q1 2026.
- Goldman Sachs bought 1,778,338 Edwards Lifesciences shares in Q1 2026, an estimated $147M.
- Edwards Lifesciences made up 0.05% of Goldman Sachs's portfolio in Q1 2026, its #404 holding.
- Goldman Sachs first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Edwards Lifesciences position peaked at $445M in Q2 2023.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.